MedTrace Logo

Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants

NCT00664716 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 391

Last updated 2016-01-21

No results posted yet for this study

Summary

Safety and efficacy of BG9924 in RA participants that have had an inadequate response to disease-modifying anti-rheumatic drug (DMARD) therapy.

Conditions

Interventions

BIOLOGICAL

Baminercept alfa 1

experimental - one dose level

BIOLOGICAL

Placebo

Placebo comparator

BIOLOGICAL

Baminercept alfa 2

experimental - second dose level

BIOLOGICAL

Baminercept alfa 3

experimental - third dose level

BIOLOGICAL

Baminercept alfa 4

experimental - fourth dose level

BIOLOGICAL

Baminercept alfa 5

experimental - fifth dose level

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Biogen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • Argentina
  • Brazil
  • Hungary
  • Mexico
  • Poland
  • Romania
  • Russia
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00664716 on ClinicalTrials.gov